Ultragenyx Pharmaceutical Inc.
$RARE
Public valuation for Ultragenyx Pharmaceutical Inc. (RARE). Fair value, signal, and key metrics — no sign-in required.
Current Price
$15.03
44% Overvalued
Fair Value Estimate
$8
🚧
Turnaround
Negative earnings but showing signs of recovery
Analyst Consensus
Target: $28.05
87% higher than current
Key Metrics
Market Cap
$1.5B
Operating Margin
-35.0%
Revenue Growth
18.4%
Get free watchlist alerts
Join the waitlist for valuation updates on $RARE and the rest of your watchlist.
Join the waitlistJoin the waitlist
Stay on this page to join — no sign-in required.